Evidence map›Paper›PMID 41972656›Full record

ArticleNanomaterials (Basel, Switzerland)2026

Lutetium-177 Radiolabeled Gold Nanoparticles for Prostate Cancer Theranostics.

Adamantia Apostolopoulou, Evangelia-Alexandra Salvanou, Christos Liolios, Stavros Xanthopoulos, Przemysław Koźmiński, Penelope Bouziotis

Abstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Adamantia ApostolopoulouRadiochemical Studies Laboratory, Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research "Demokritos", Agia Paraskevi, 15341 Athens, Greece.ORCID 0000-0003-1433-2949
Evangelia-Alexandra SalvanouRadiochemical Studies Laboratory, Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research "Demokritos", Agia Paraskevi, 15341 Athens, Greece.ORCID 0009-0001-2091-0234
Christos LioliosRadiochemical Studies Laboratory, Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research "Demokritos", Agia Paraskevi, 15341 Athens, Greece.
Stavros XanthopoulosRadiochemical Studies Laboratory, Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research "Demokritos", Agia Paraskevi, 15341 Athens, Greece.
Przemysław KoźmińskiCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.ORCID 0000-0003-0471-6949
Penelope BouziotisRadiochemical Studies Laboratory, Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research "Demokritos", Agia Paraskevi, 15341 Athens, Greece.ORCID 0000-0001-6778-2201

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gold nanoparticles (AuNPs) have been extensively studied in cancer treatment research since they have special physicochemical characteristics such as facile surface functionalization with various chemical groups, low toxicity, favorable biocompatibility, and the ability to passively accumulate in tumors through the enhanced permeability and retention (EPR) effect. Prostate cancer cells exhibit an overexpression of the Prostate-Specific Membrane Antigen (PSMA), which therefore represents an ideal candidate for the development of nanoplatforms targeting PSMA overexpressed on these cells. Lutetium-177 (

Indexed as

cell bindingcell internalizationgold nanoparticleslutetium-177MTT assayprostate cancerPSMAradiolabelingspheroids

Identifiers

PMID41972656
PMCPMC13074626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.